Table 3 Selected ongoing phase II/III studies with PARP inhibitors in gBRCA1/2m early-stage breast cancer

From: BRCA1/2 testing: therapeutic implications for breast cancer management

Study

Disease

Phase

N

Treatment

Status

OlympiA NCT0203282392

gBRCA1/2m with either TNBC or ER+ and/or PgR+ and HER2-negative BC

III

1500 (est)

Olaparib tablets vs placebo after surgery and at least 6 cycles of neoadjuvant or adjuvant chemotherapy

ONGOING

NCT0228234591

gBRCA1/2m stage I–III BC ≥1 cm, HER2-negative

II

36

Neoadjuvant talazoparib 1 mg (monotherapy) up to 6 months

ONGOING

BRE09-146 NCT0107497093

TNBC or gBRCA1/2m HER2-negative BC with residual disease after neoadjuvant chemotherapy

II

135

Cisplatin IV every 21 days for 4 cycles vs cisplatin (same dose) plus rucaparib on days 1, 2, 3 every 21 days for 4 cycles

ONGOING

  1. BC breast cancer, ER+ oestrogen receptor-positive, est estimated, gBRCA1/2m germline BRCA mutation, HER2 human epidermal growth factor receptor 2, PgR+ progesterone receptor-positive, TNBC triple-negative BC
Back to article page